Clearstead Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $67.4K | Buy |
224
+108
| +93% | +$32.6K | ﹤0.01% | 1400 |
|
|
2026
Q1 | $38.4K | Sell |
116
-31
| -21% | -$10.5K | ﹤0.01% | 1330 |
|
|
2025
Q4 | $58.5K | Sell |
147
-617
| -81% | -$273K | ﹤0.01% | 1333 |
|
|
2025
Q3 | $348K | Sell |
764
-359
| -32% | -$146K | ﹤0.01% | 740 |
|
|
2025
Q2 | $366K | Sell |
1,123
-181
| -14% | -$50.1K | 0.01% | 697 |
|
|
2025
Q1 | $352K | Buy |
1,304
+194
| +17% | +$49.9K | 0.01% | 663 |
|
|
2024
Q4 | $261K | Hold |
1,110
| – | – | ﹤0.01% | 774 |
|
|
2024
Q3 | $305K | Hold |
1,110
| – | – | ﹤0.01% | 721 |
|
|
2024
Q2 | $270K | Buy |
1,110
+1,000
| +909% | +$158K | ﹤0.01% | 720 |
|
|
2024
Q1 | $16.5K | Sell |
110
-708
| -87% | -$118K | ﹤0.01% | 973 |
|
|
2023
Q4 | $157K | Sell |
818
-700
| -46% | -$119K | 0.01% | 494 |
|
|
2023
Q3 | $269K | Hold |
1,518
| – | – | 0.02% | 382 |
|
|
2023
Q2 | $288K | Hold |
1,518
| – | – | 0.02% | 377 |
|
|
2023
Q1 | $304K | Buy |
1,518
+10
| +0.7% | +$2.1K | 0.02% | 337 |
|
|
2022
Q4 | $358K | Hold |
1,508
| – | – | 0.03% | 300 |
|
|
2022
Q3 | $302K | Sell |
1,508
-3,040
| -67% | -$580K | 0.03% | 308 |
|
|
2022
Q2 | $663K | Buy |
4,548
+40
| +0.9% | +$5.67K | 0.05% | 215 |
|
|
2022
Q1 | $736K | Buy |
4,508
+1,398
| +45% | +$213K | 0.05% | 220 |
|
|
2021
Q4 | $527K | Buy |
3,110
+110
| +4% | +$20.4K | 0.04% | 250 |
|
|
2021
Q3 | $566K | Hold |
3,000
| – | – | 0.04% | 227 |
|
|
2021
Q2 | $509K | Hold |
3,000
| – | – | 0.04% | 228 |
|
|
2021
Q1 | $424K | Hold |
3,000
| – | – | 0.04% | 238 |
|
|
2020
Q4 | $390K | Hold |
3,000
| – | – | 0.04% | 230 |
|
|
2020
Q3 | $437K | Hold |
3,000
| – | – | 0.05% | 193 |
|
|
2020
Q2 | $444K | Hold |
3,000
| – | – | 0.05% | 187 |
|
|
2020
Q1 | $327K | Hold |
3,000
| – | – | 0.05% | 189 |
|
|
2019
Q4 | $346K | Hold |
3,000
| – | – | 0.04% | 211 |
|
|
2019
Q3 | $241K | Hold |
3,000
| – | – | 0.03% | 233 |
|
|
2019
Q2 | $218K | Hold |
3,000
| – | – | 0.03% | 255 |
|
|
2019
Q1 | $280K | Hold |
3,000
| – | – | 0.04% | 221 |
|
|
2018
Q4 | $219K | Hold |
3,000
| – | – | 0.03% | 232 |
|
|
2018
Q3 | $263K | Hold |
3,000
| – | – | 0.04% | 204 |
|
|
2018
Q2 | $295K | Hold |
3,000
| – | – | 0.04% | 193 |
|
|
2018
Q1 | $357K | Hold |
3,000
| – | – | 0.05% | 167 |
|
|
2017
Q4 | $381K | Hold |
3,000
| – | – | 0.05% | 162 |
|
|
2017
Q3 | $352K | Hold |
3,000
| – | – | 0.05% | 180 |
|
|
2017
Q2 | $239K | Buy |
+3,000
| New | +$192K | 0.03% | 210 |
|
Other funds holding ALNY
Clearstead Advisors's ALNY Position: Q2 2026 in Review
Clearstead Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 93% in Q2 2026, buying an estimated $32.6K and bringing the position to 224 shares worth $67.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1400.
Clearstead Advisors first reported a position in ALNY in Q2 2017 and has held it in 37 quarters since. The position peaked at $736K in Q1 2022. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Clearstead Advisors held 224 shares of Alnylam Pharmaceuticals worth $67.4K as of Q2 2026.
- Clearstead Advisors bought 108 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $32.6K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1400 holding.
- Clearstead Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2017 and has held it in 37 quarters since.
- Clearstead Advisors's Alnylam Pharmaceuticals position peaked at $736K in Q1 2022.
- 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.